DE08786222T1 - Neue albuminbindende zusammensetzungen, verfahren und anwendungen - Google Patents
Neue albuminbindende zusammensetzungen, verfahren und anwendungen Download PDFInfo
- Publication number
- DE08786222T1 DE08786222T1 DE08786222T DE08786222T DE08786222T1 DE 08786222 T1 DE08786222 T1 DE 08786222T1 DE 08786222 T DE08786222 T DE 08786222T DE 08786222 T DE08786222 T DE 08786222T DE 08786222 T1 DE08786222 T1 DE 08786222T1
- Authority
- DE
- Germany
- Prior art keywords
- albumin
- binding polypeptide
- binding
- seq
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000009027 Albumins Human genes 0.000 title claims abstract 122
- 108010088751 Albumins Proteins 0.000 title claims abstract 122
- 230000027455 binding Effects 0.000 title claims abstract 118
- 239000000203 mixture Substances 0.000 title claims 37
- 238000000034 method Methods 0.000 title claims 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 105
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract 104
- 229920001184 polypeptide Polymers 0.000 claims abstract 103
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 17
- 150000001875 compounds Chemical class 0.000 claims 19
- 239000012634 fragment Substances 0.000 claims 11
- 230000003993 interaction Effects 0.000 claims 10
- 108020001507 fusion proteins Proteins 0.000 claims 9
- 102000037865 fusion proteins Human genes 0.000 claims 9
- 102000004169 proteins and genes Human genes 0.000 claims 9
- 108090000623 proteins and genes Proteins 0.000 claims 9
- 102000008100 Human Serum Albumin Human genes 0.000 claims 8
- 108091006905 Human Serum Albumin Proteins 0.000 claims 8
- 102000005962 receptors Human genes 0.000 claims 8
- 108020003175 receptors Proteins 0.000 claims 8
- 125000000539 amino acid group Chemical group 0.000 claims 7
- 150000001413 amino acids Chemical class 0.000 claims 7
- 230000004071 biological effect Effects 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 6
- 108020001580 protein domains Proteins 0.000 claims 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 6
- 241000194017 Streptococcus Species 0.000 claims 5
- 101710120037 Toxin CcdB Proteins 0.000 claims 5
- 241000191940 Staphylococcus Species 0.000 claims 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 3
- 230000001580 bacterial effect Effects 0.000 claims 3
- 230000008878 coupling Effects 0.000 claims 3
- 238000010168 coupling process Methods 0.000 claims 3
- 238000005859 coupling reaction Methods 0.000 claims 3
- 229940127089 cytotoxic agent Drugs 0.000 claims 3
- 231100000599 cytotoxic agent Toxicity 0.000 claims 3
- 239000002254 cytotoxic agent Substances 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 239000013604 expression vector Substances 0.000 claims 3
- 238000001727 in vivo Methods 0.000 claims 3
- 239000000178 monomer Substances 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- -1 tendamistaten Proteins 0.000 claims 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 2
- 102000008102 Ankyrins Human genes 0.000 claims 2
- 108010049777 Ankyrins Proteins 0.000 claims 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims 2
- 102000014914 Carrier Proteins Human genes 0.000 claims 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 102000002090 Fibronectin type III Human genes 0.000 claims 2
- 108050009401 Fibronectin type III Proteins 0.000 claims 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 2
- 102000019298 Lipocalin Human genes 0.000 claims 2
- 108050006654 Lipocalin Proteins 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 102000000470 PDZ domains Human genes 0.000 claims 2
- 108050008994 PDZ domains Proteins 0.000 claims 2
- 108010079855 Peptide Aptamers Proteins 0.000 claims 2
- 241000191967 Staphylococcus aureus Species 0.000 claims 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 2
- 108091008324 binding proteins Proteins 0.000 claims 2
- 239000003114 blood coagulation factor Substances 0.000 claims 2
- 229940019700 blood coagulation factors Drugs 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 229920002678 cellulose Polymers 0.000 claims 2
- 239000001913 cellulose Substances 0.000 claims 2
- 239000013078 crystal Substances 0.000 claims 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims 2
- 239000005090 green fluorescent protein Substances 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 210000002500 microbody Anatomy 0.000 claims 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 2
- 229910052725 zinc Inorganic materials 0.000 claims 2
- 239000011701 zinc Substances 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 claims 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 231100000699 Bacterial toxin Toxicity 0.000 claims 1
- 102100024217 CAMPATH-1 antigen Human genes 0.000 claims 1
- 101150013553 CD40 gene Proteins 0.000 claims 1
- 108010065524 CD52 Antigen Proteins 0.000 claims 1
- 102100025221 CD70 antigen Human genes 0.000 claims 1
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims 1
- 102000001301 EGF receptor Human genes 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 241001617393 Finegoldia Species 0.000 claims 1
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 claims 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 1
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 claims 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 1
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 claims 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims 1
- 101000910338 Homo sapiens Carbonic anhydrase 9 Proteins 0.000 claims 1
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims 1
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims 1
- 101100118549 Homo sapiens EGFR gene Proteins 0.000 claims 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 1
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 1
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 102000019223 Interleukin-1 receptor Human genes 0.000 claims 1
- 108050006617 Interleukin-1 receptor Proteins 0.000 claims 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 claims 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 claims 1
- 108090001007 Interleukin-8 Proteins 0.000 claims 1
- 108010063738 Interleukins Proteins 0.000 claims 1
- 102000015696 Interleukins Human genes 0.000 claims 1
- 108010047357 Luminescent Proteins Proteins 0.000 claims 1
- 102000006830 Luminescent Proteins Human genes 0.000 claims 1
- 108010059724 Micrococcal Nuclease Proteins 0.000 claims 1
- 102100034256 Mucin-1 Human genes 0.000 claims 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 1
- 108010056852 Myostatin Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 101710163270 Nuclease Proteins 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 241000191992 Peptostreptococcus Species 0.000 claims 1
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims 1
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 claims 1
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 claims 1
- 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 claims 1
- 241000270295 Serpentes Species 0.000 claims 1
- 108700011201 Streptococcus IgG Fc-binding Proteins 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 108010044540 auristatin Proteins 0.000 claims 1
- 239000000688 bacterial toxin Substances 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 230000003292 diminished effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 239000000975 dye Substances 0.000 claims 1
- 230000002255 enzymatic effect Effects 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 claims 1
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 claims 1
- 229960001340 histamine Drugs 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 229940047122 interleukins Drugs 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 150000002739 metals Chemical class 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 108010025221 plasma protein Z Proteins 0.000 claims 1
- 231100000614 poison Toxicity 0.000 claims 1
- 239000002574 poison Substances 0.000 claims 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 1
- 230000000770 proinflammatory effect Effects 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
- 229940044601 receptor agonist Drugs 0.000 claims 1
- 230000009834 selective interaction Effects 0.000 claims 1
- 238000004904 shortening Methods 0.000 claims 1
- 230000006641 stabilisation Effects 0.000 claims 1
- 238000011105 stabilization Methods 0.000 claims 1
- 101150047061 tag-72 gene Proteins 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
- PKVRCIRHQMSYJX-AIFWHQITSA-N trabectedin Chemical compound C([C@@]1(C(OC2)=O)NCCC3=C1C=C(C(=C3)O)OC)S[C@@H]1C3=C(OC(C)=O)C(C)=C4OCOC4=C3[C@H]2N2[C@@H](O)[C@H](CC=3C4=C(O)C(OC)=C(C)C=3)N(C)[C@H]4[C@@H]21 PKVRCIRHQMSYJX-AIFWHQITSA-N 0.000 claims 1
- 229960000977 trabectedin Drugs 0.000 claims 1
- 230000001960 triggered effect Effects 0.000 claims 1
- 108010047303 von Willebrand Factor Proteins 0.000 claims 1
- 102100036537 von Willebrand factor Human genes 0.000 claims 1
- 229960001134 von willebrand factor Drugs 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96261807P | 2007-07-31 | 2007-07-31 | |
| EP07113533 | 2007-07-31 | ||
| US962618P | 2007-07-31 | ||
| EP07113533 | 2007-07-31 | ||
| PCT/EP2008/059389 WO2009016043A2 (en) | 2007-07-31 | 2008-07-17 | New albumin binding compositions, methods and uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE08786222T1 true DE08786222T1 (de) | 2010-11-25 |
Family
ID=40057660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE08786222T Pending DE08786222T1 (de) | 2007-07-31 | 2008-07-17 | Neue albuminbindende zusammensetzungen, verfahren und anwendungen |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US8937153B2 (enExample) |
| EP (2) | EP2190863B1 (enExample) |
| JP (1) | JP5718638B2 (enExample) |
| CN (2) | CN104710518A (enExample) |
| AU (1) | AU2008281913B2 (enExample) |
| CA (1) | CA2694139C (enExample) |
| DE (1) | DE08786222T1 (enExample) |
| DK (1) | DK2190863T3 (enExample) |
| ES (1) | ES2346178T3 (enExample) |
| HK (1) | HK1211040A1 (enExample) |
| WO (1) | WO2009016043A2 (enExample) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2346178T3 (es) * | 2007-07-31 | 2015-11-02 | Affibody Ab | Nuevas composiciones, procedimientos y usos de unión de la albúmina |
| US20120134984A1 (en) * | 2009-06-01 | 2012-05-31 | Olga Lubman | Molecules with extended half-lives and uses thereof |
| JP5951509B2 (ja) * | 2010-03-08 | 2016-07-13 | ジーイー・ヘルスケア・バイオサイエンス・アクチボラグ | 免疫グロブリンＧＦｃ領域結合ポリペプチド |
| CA2793715A1 (en) * | 2010-04-30 | 2011-11-03 | Sanwa Kagaku Kenkyusho Co., Ltd. | Peptide for improving in vivo stability of physiologically active substance or the like and physiologically active substance with improved in vivo stability |
| KR101884654B1 (ko) | 2010-07-09 | 2018-08-02 | 애피바디 에이비 | 폴리펩타이드 |
| SG187682A1 (en) * | 2010-08-02 | 2013-03-28 | Macrogenics Inc | Covalent diabodies and uses thereof |
| CA2813087C (en) | 2010-09-28 | 2020-07-21 | Amylin Pharmaceuticals, Llc | Engineered polypeptides having enhanced duration of action |
| JP6121330B2 (ja) | 2010-09-28 | 2017-04-26 | アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc | 作用持続時間が増した改変ポリペプチド |
| US9284361B2 (en) | 2010-11-26 | 2016-03-15 | Molecular Partners Ag | Designed repeat proteins binding to serum albumin |
| CA2836873C (en) * | 2011-05-21 | 2019-10-22 | Macrogenics, Inc. | Deimmunized serum-binding domains and their use for extending serum half-life |
| CN103957926B (zh) * | 2011-07-08 | 2018-07-03 | 安米林药品有限责任公司 | 具有增强的作用持续时间和降低的免疫原性的工程改造的多肽 |
| JP6006309B2 (ja) * | 2011-07-08 | 2016-10-12 | アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc | 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド |
| SMT201900189T1 (it) | 2012-02-20 | 2019-05-10 | Swedish Orphan Biovitrum Ab Publ | Polipeptidi che si legano al c5 del complemento umano |
| JP2020033372A (ja) * | 2012-03-28 | 2020-03-05 | アフィボディ・アーベー | 経口投与 |
| EP2844269A4 (en) * | 2012-03-28 | 2016-01-06 | Amylin Pharmaceuticals Llc | TRANSMUCOSAL ADMINISTRATION OF MANIPULATED POLYPEPTIDES |
| EP2830665A1 (en) | 2012-03-28 | 2015-02-04 | Affibody AB | Oral administration |
| WO2013177398A2 (en) | 2012-05-25 | 2013-11-28 | Janssen Biotech, Inc. | Non-natural consensus albumin binding domains |
| KR102123457B1 (ko) * | 2012-09-25 | 2020-06-16 | 애피바디 에이비 | 알부민 결합 폴리펩타이드 |
| CN104768976B (zh) | 2012-10-05 | 2020-09-22 | 阿菲博迪公司 | Her3结合多肽 |
| PL2912051T3 (pl) * | 2012-10-25 | 2018-08-31 | Affibody Ab | Sposób rozdzielania białek zawierających domenę wiążącą albuminę |
| DK2912054T3 (en) * | 2012-10-25 | 2017-09-11 | Affibody Ab | Albumin-binding polypeptide |
| WO2014076179A1 (en) | 2012-11-14 | 2014-05-22 | Affibody Ab | New polypeptide |
| US9255262B2 (en) | 2013-03-06 | 2016-02-09 | Vision Global Holdings Ltd. | Albumin-binding arginine deminase and the use thereof |
| USRE48805E1 (en) | 2013-03-06 | 2021-11-02 | Vision Global Holdings Ltd. | Method for cancer targeting treatment and detection of arginine using albumin-binding arginine deiminase fusion protein |
| CA2902789A1 (en) | 2013-03-14 | 2014-09-18 | The Governing Council Of The University Of Toronto | Scaffolded peptidic libraries and methods of making and screening the same |
| RU2015142437A (ru) | 2013-03-14 | 2017-04-27 | Дайити Санкио Ко., Лтд | Новые связывающие белки для pcsk9 |
| CA2902657C (en) | 2013-03-15 | 2022-05-10 | Affibody Ab | Fcrn binding polypeptides |
| HK1215681A1 (zh) | 2013-04-18 | 2016-09-09 | Armo Biosciences, Inc. | 使用白细胞介素-10治疗疾病和病症的方法 |
| ES2688206T3 (es) | 2013-06-17 | 2018-10-31 | Armo Biosciences, Inc. | Procedimiento de evaluación de la identidad y la estabilidad de proteínas |
| DK3038633T3 (da) | 2013-08-28 | 2021-01-11 | Ipc Res Llc | Stabile polypeptider der binder til human komplement c5 |
| ES2742505T3 (es) | 2013-08-28 | 2020-02-14 | Affibody Ab | Polipéptidos de unión que tienen un andamio mutado |
| CN105658232A (zh) | 2013-08-30 | 2016-06-08 | 阿尔莫生物科技股份有限公司 | 使用白细胞介素-10治疗疾病和病症的方法 |
| ES2862139T3 (es) | 2013-11-11 | 2021-10-07 | Armo Biosciences Inc | Procedimientos de uso de Interleucina 10 para el tratamiento de enfermedades y trastornos |
| US10167322B2 (en) | 2013-12-20 | 2019-01-01 | Affibody Ab | Engineered albumin binding polypeptide |
| US10293043B2 (en) | 2014-06-02 | 2019-05-21 | Armo Biosciences, Inc. | Methods of lowering serum cholesterol |
| UA123432C2 (uk) | 2014-07-30 | 2021-04-07 | Нджм Біофармасьютікалз, Інк. | Димер та спосіб його застосування для лікування метаболічних розладів |
| US10323066B2 (en) | 2014-09-17 | 2019-06-18 | Affibody Ab | Neonatal Fc receptor binding dimer and methods of use |
| KR20170068553A (ko) | 2014-10-14 | 2017-06-19 | 아르모 바이오사이언시스 인코포레이티드 | 인터류킨-15 조성물 및 이의 용도 |
| MX2017004983A (es) | 2014-10-22 | 2017-11-13 | Armo Biosciences Inc | Metodos para usar interleucina 10 para tratar enfermedades y trastornos. |
| ES2799503T3 (es) | 2014-10-31 | 2020-12-18 | Ngm Biopharmaceuticals Inc | Composiciones y procedimientos de uso para el tratamiento de trastornos metabólicos |
| DK3245224T3 (da) | 2015-01-12 | 2020-09-21 | Affibody Ab | Il-17a-bindende polypeptider |
| US10618970B2 (en) | 2015-02-03 | 2020-04-14 | Armo Biosciences, Inc. | Method of treating cancer with IL-10 and antibodies that induce ADCC |
| US11052133B2 (en) | 2015-05-06 | 2021-07-06 | Protomer Technologies, Inc. | Glucose responsive insulins |
| HK1248137A1 (zh) | 2015-05-28 | 2018-10-12 | 阿尔莫生物科技股份有限公司 | 用於治疗癌症的聚乙二醇化白细胞介素-10 |
| CN108463244B (zh) | 2015-08-04 | 2022-05-27 | 杜克大学 | 用于递送的基因编码的固有无序隐形聚合物及其使用方法 |
| MX2018002298A (es) | 2015-08-25 | 2018-07-06 | Armo Biosciences Inc | Metodos de uso de interleucina 10 para el tratamiento de enfermedades y trastornos. |
| US11752213B2 (en) | 2015-12-21 | 2023-09-12 | Duke University | Surfaces having reduced non-specific binding and antigenicity |
| CN107022031A (zh) * | 2016-01-29 | 2017-08-08 | 中国人民解放军军事医学科学院微生物流行病研究所 | 融合蛋白HSA1-Vβ1及其应用 |
| WO2017210476A1 (en) | 2016-06-01 | 2017-12-07 | Duke University | Nonfouling biosensors |
| CN110023326A (zh) | 2016-09-23 | 2019-07-16 | 杜克大学 | 具有lcst行为的非结构化无重复多肽 |
| CN107952080A (zh) * | 2016-10-14 | 2018-04-24 | 中国科学院过程工程研究所 | 一种肿瘤靶向多肽-药物偶联衍生物、其制备方法及应用 |
| US11648200B2 (en) | 2017-01-12 | 2023-05-16 | Duke University | Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly |
| WO2018213320A1 (en) | 2017-05-15 | 2018-11-22 | Duke University | Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents |
| US11680083B2 (en) | 2017-06-30 | 2023-06-20 | Duke University | Order and disorder as a design principle for stimuli-responsive biopolymer networks |
| WO2019032827A1 (en) * | 2017-08-09 | 2019-02-14 | Massachusetts Institute Of Technology | PEPTIDE ALBUMIN BINDING CONJUGATES AND METHODS THEREOF |
| US20200239575A1 (en) * | 2017-10-06 | 2020-07-30 | University Of Utah Research Foundation | A fusion protein for targeted therapy of autoimmune disease |
| WO2019071150A1 (en) * | 2017-10-06 | 2019-04-11 | University Of Utah Research Foundation | FUSION PROTEIN FOR TARGETED THERAPY OF AUTOIMMUNE DISEASE |
| WO2019147954A1 (en) * | 2018-01-26 | 2019-08-01 | Duke University | Albumin binding peptide-drug (aibiped) conjugates and methods of making and using same |
| EP3765496A1 (en) | 2018-03-13 | 2021-01-20 | Affibody AB | Polypeptides based on a novel scaffold |
| WO2019213150A1 (en) | 2018-04-30 | 2019-11-07 | Duke University | Stimuli-responsive peg-like polymer-based drug delivery platform |
| WO2020028806A1 (en) | 2018-08-02 | 2020-02-06 | Duke University | Dual agonist fusion proteins |
| WO2020051541A1 (en) * | 2018-09-07 | 2020-03-12 | Duke University | Nanoparticulate drug delivery systems |
| WO2020176478A1 (en) | 2019-02-25 | 2020-09-03 | The University Of Chicago | Methods and compositions for treating inflammatory and autoimmune conditions with ecm-affinity peptides linked to anti-inflammatory agents |
| CA3138805A1 (en) | 2019-06-04 | 2020-12-10 | Johannes Schilling | Designed ankyrin repeat domain with improved stability |
| US11512314B2 (en) | 2019-07-12 | 2022-11-29 | Duke University | Amphiphilic polynucleotides |
| EP3785726A1 (en) | 2019-09-02 | 2021-03-03 | Biotest AG | Factor viii protein with increased half-life |
| JP2022546525A (ja) | 2019-09-02 | 2022-11-04 | ビオテスト・アクチエンゲゼルシャフト | 延長された半減期を有する第ｖｉｉｉ因子タンパク質 |
| US20220389066A1 (en) | 2019-11-05 | 2022-12-08 | Affibody Ab | Polypeptides |
| US20230190881A1 (en) | 2020-02-17 | 2023-06-22 | Biotest Ag | Subcutaneous administration of factor viii |
| EP3878515A1 (en) * | 2020-03-09 | 2021-09-15 | Hober Biotech AB | Therapeutic agent targeting her2 |
| WO2022098743A1 (en) | 2020-11-03 | 2022-05-12 | Indi Molecular, Inc. | Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1) |
| WO2022098745A1 (en) | 2020-11-03 | 2022-05-12 | Indi Molecular, Inc. | Compositions, delivery systems, and methods useful in tumor therapy |
| KR20230123989A (ko) | 2020-12-21 | 2023-08-24 | 애피바디 에이비 | 신규 폴리펩티드 |
| JP2024506070A (ja) | 2021-02-15 | 2024-02-08 | アフィボディ アクティエボラーグ | 新規ｈｅｒ２結合ポリペプチド |
| KR20240139058A (ko) | 2022-02-08 | 2024-09-20 | 애피바디 에이비 | 흉선 기질 림포포이에틴에 결합하는 단백질 z 변이체 및 이의 의학적 용도 |
| EP4525919A1 (en) | 2022-05-18 | 2025-03-26 | Protomer Technologies Inc. | Aromatic boron-containing compounds and related insulin analogs |
| EP4570834A1 (en) | 2022-08-10 | 2025-06-18 | Kowa Company, Ltd. | Affibody micelle drug conjugate |
| CN120712282A (zh) | 2023-02-17 | 2025-09-26 | 阿布林克斯有限公司 | 结合新生儿fc受体的多肽 |
| WO2024227930A1 (en) | 2023-05-04 | 2024-11-07 | Affibody Ab | New polypeptide |
| WO2025073871A1 (en) | 2023-10-03 | 2025-04-10 | Bicycletx Limited | Bicyclic peptide ligand complexes specific for tfr1 |
| WO2025158010A1 (en) | 2024-01-25 | 2025-07-31 | Affibody Ab | Her2-binding polypeptide |
| CN118666961B (zh) * | 2024-08-23 | 2024-11-26 | 通化安睿特生物制药股份有限公司 | 人白蛋白特异结合多肽及其应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
| FR2718452B1 (fr) * | 1994-04-06 | 1996-06-28 | Pf Medicament | Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation. |
| FR2726471B1 (fr) * | 1994-11-07 | 1997-01-31 | Pf Medicament | Procede pour ameliorer l'immunogenicite d'un compose immunogene ou d'un haptene et application a la preparation de vaccins |
| DE19742706B4 (de) * | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| GB9823071D0 (en) * | 1998-10-21 | 1998-12-16 | Affibody Technology Ab | A method |
| GB9911287D0 (en) * | 1999-05-14 | 1999-07-14 | Affibody Technology Sweden Ab | Self-assembling protein structures |
| AU784285B2 (en) | 1999-12-24 | 2006-03-02 | Genentech Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
| US20040001827A1 (en) | 2002-06-28 | 2004-01-01 | Dennis Mark S. | Serum albumin binding peptides for tumor targeting |
| CN1169827C (zh) | 2001-08-07 | 2004-10-06 | 沈阳三生制药股份有限公司 | 一种增强多肽在体内稳定性药物的生产方法及其应用 |
| WO2003029462A1 (en) * | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| US7118915B2 (en) * | 2001-09-27 | 2006-10-10 | Pieris Proteolab Ag | Muteins of apolipoprotein D |
| SE0400274D0 (sv) * | 2004-02-09 | 2004-02-09 | Affibody Ab | New polypeptide |
| JP5634008B2 (ja) | 2004-04-06 | 2014-12-03 | アフィボディ・アーベー | 新規の使用および方法 |
| US7892827B2 (en) | 2004-11-26 | 2011-02-22 | Pieris Ag | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
| ES2346178T3 (es) * | 2007-07-31 | 2015-11-02 | Affibody Ab | Nuevas composiciones, procedimientos y usos de unión de la albúmina |
| EP2496598B1 (en) * | 2009-11-04 | 2017-08-02 | Affibody AB | Her3 binding polypeptides |
-
2008
- 2008-07-17 ES ES08786222.3T patent/ES2346178T3/es active Active
- 2008-07-17 CN CN201510071238.8A patent/CN104710518A/zh active Pending
- 2008-07-17 JP JP2010518606A patent/JP5718638B2/ja active Active
- 2008-07-17 US US12/452,731 patent/US8937153B2/en active Active
- 2008-07-17 CA CA2694139A patent/CA2694139C/en active Active
- 2008-07-17 AU AU2008281913A patent/AU2008281913B2/en active Active
- 2008-07-17 CN CN200880101168.4A patent/CN101765608B/zh active Active
- 2008-07-17 DK DK08786222.3T patent/DK2190863T3/da active
- 2008-07-17 EP EP08786222.3A patent/EP2190863B1/en active Active
- 2008-07-17 EP EP12176805.5A patent/EP2546261A3/en not_active Withdrawn
- 2008-07-17 WO PCT/EP2008/059389 patent/WO2009016043A2/en not_active Ceased
- 2008-07-17 DE DE08786222T patent/DE08786222T1/de active Pending
-
2014
- 2014-11-24 US US14/551,931 patent/US10118949B2/en active Active
-
2015
- 2015-12-02 HK HK15111838.6A patent/HK1211040A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2546261A2 (en) | 2013-01-16 |
| EP2546261A3 (en) | 2013-08-14 |
| HK1211040A1 (en) | 2016-05-13 |
| WO2009016043A2 (en) | 2009-02-05 |
| CA2694139A1 (en) | 2009-02-05 |
| ES2346178T3 (es) | 2015-11-02 |
| CN104710518A (zh) | 2015-06-17 |
| AU2008281913B2 (en) | 2013-11-07 |
| EP2190863A2 (en) | 2010-06-02 |
| US20150158916A1 (en) | 2015-06-11 |
| US20100273979A1 (en) | 2010-10-28 |
| DK2190863T3 (en) | 2015-11-30 |
| CN101765608B (zh) | 2015-03-11 |
| CN101765608A (zh) | 2010-06-30 |
| EP2190863B1 (en) | 2015-09-02 |
| AU2008281913A1 (en) | 2009-02-05 |
| US10118949B2 (en) | 2018-11-06 |
| WO2009016043A3 (en) | 2009-06-04 |
| JP2010534486A (ja) | 2010-11-11 |
| ES2346178T1 (es) | 2010-10-13 |
| US8937153B2 (en) | 2015-01-20 |
| CA2694139C (en) | 2018-06-05 |
| JP5718638B2 (ja) | 2015-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE08786222T1 (de) | Neue albuminbindende zusammensetzungen, verfahren und anwendungen | |
| DE69002395T2 (de) | N-terminale Fragmente von menschliches Serumalbumin enthaltenden Fusionsproteinen. | |
| DE69232137T2 (de) | Multivalente antigen-bindende proteine | |
| DE69333622T2 (de) | Neuartige, biologisch aktive polypeptide, ihre herstellung und diese polypeptide enthaltende pharmazeutische zusammensetzung | |
| DE69131449T2 (de) | Verbesserte exotoxine aus pseudomonas mit geringer toxität bei tieren und hoher zelltötender aktivität | |
| EP0980874B1 (de) | Verbessertes Verfahren zur Gewinnung von Insulinvorläufern mit korrekt verbundenen Cystinbrücken | |
| AU2017311040B2 (en) | In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use | |
| DE69934425T2 (de) | Thrombopoietin substitute | |
| DE602004011770T2 (de) | Fusionsproteine | |
| DE68913771T2 (de) | Für IG-CD4 Fusionsproteine kodierende, klonierte Gene und deren Verwendung. | |
| DE60102899T2 (de) | Verfahren zur lösung von glucagon-ähnlichen peptid-1 (glp-1) verbindungen | |
| DE68928810T2 (de) | Analoge vom menschlichen Insulin | |
| DE69015811T2 (de) | Insulinverbindungen. | |
| RU2013102953A (ru) | Полипептиды | |
| DE69532436T2 (de) | Einzelkettenformen des clycoprotein-hormon-quartetts | |
| DE69628576T2 (de) | Procollagene | |
| DD273839A5 (de) | Verfahren zur herstellung neuer insulinderivate | |
| EP0411096A1 (de) | Pth-varianten kodierende dna-sequenzen, pth-varianten, expressionsvektor, bakterieller wirt, verwendung und therapeutische zusammensetzung | |
| EP1353948B1 (de) | Lösliche cyclische analoga des beta amyloiden peptids | |
| DE69132813T2 (de) | Genetisches igfbp-5 rodierendes material | |
| DE60031990T2 (de) | Synthetische verbindungen mit zwei epitopen für immunoassays | |
| CA2199180A1 (en) | Method of blocking the sec receptor | |
| DE69025211T2 (de) | Protein-Antikrebsmittel | |
| DE69131979T2 (de) | Genetisches igfbp-4 rodierendes material | |
| DE19856052A1 (de) | Konjugat zur Anreicherung in neuronalen Zellen |